QuantLogix ← GILD scorecard
📅 GILD Earnings Preview
Gilead Sciences Inc
Next report (est.)
11/30/2026
Countdown
79 days
EPS growth YoY
-641.7%
Revenue growth YoY
+10.2%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/06/2026 ±3.6% -0.7% over-priced
05/07/2026 ±2.4% -1.6% over-priced
11/07/2025 ±3.2% -3.7% under-priced
08/07/2025 ±2.1% +0.0% over-priced
05/07/2025 ±3.3% +1.0% over-priced
11/12/2024 ±3.2% -2.8% over-priced
08/08/2024 ±2.6% +2.1% over-priced
05/08/2024 ±1.6% -0.8% over-priced
Across these reports, options implied an average ±2.8% move vs an actual average of 1.6% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $-8.45 $7.8B $-10.5B
Q1 FY2026 $1.61 $7.0B $2.0B
Q4 FY2025 $1.74 $7.9B $2.2B
Q3 FY2025 $2.43 $7.8B $3.1B
Analyst posture
Buy / Strong Buy
30
Hold
7
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Buy · 63/100 Full scorecard →
Get alerted before every GILD report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on GILD before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Gilead Sciences Inc (GILD) reports in 79 days, with the next report estimated for 11/30/2026. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 1.6% on average — the market has systematically over-priced GILD's earnings risk. Fundamentals into the print: EPS down 641.7% year-over-year, revenue up 10.2%. QuantLogix's live 5-factor engine currently reads GILD as a buy at 63/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →